Knotless Tissue Control Devices Market By Product Type (Absorbable Knotless Tissue Control Devices, Non-absorbable Knotless Tissue Control Devices); By Application (General and Abdominal Surgery, Obstetrics and Gynecology, Orthopedic Surgery, Bariatric Surgery, Hernia Repair, Colorectal Surgery, Urological Surgery, Cardiovascular Surgery, Plastic and Reconstructive Surgery); By End User (Hospitals, Ambulatory Surgery Centers, Specialty Surgical Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Knotless Tissue Control Devices Market: Surgical Efficiency, Procedure Growth, and Wound-Closure Competition

The Global Knotless Tissue Control Devices Market is projected to grow from USD 2.28 billion in 2025 to USD 4.40 billion by 2032, expanding at a CAGR of 8.5% from 2026 to 2032, according to Strategic Market Research. The forecast represents an additional USD 2.12 billion in annual market revenue and a total expansion of approximately 93% over the seven-year period.

 

Demand is tied directly to surgical activity because each device is consumed during a procedure. Market growth therefore depends on procedure volume, closure technique, surgeon preference, hospital procurement, product indication, and the number of devices used per case. The category benefits from recurring purchasing across hospitals and ambulatory surgery centers rather than capital-equipment replacement cycles.

 

Knotless devices compete within the wider surgical-suture market, but their commercial proposition is more focused. They help maintain tissue tension without repeated knot formation, allowing surgeons to complete selected closures more quickly. Hospitals assess them against operating-room time, wound outcomes, staffing pressure, material cost, and suitability for open, laparoscopic, and robotic surgery.

 

Operating-Room Economics Strengthen Adoption

The strongest commercial argument for knotless sutures is their ability to reduce closure time while maintaining secure tissue approximation. Operating-room time carries anesthesia, staffing, equipment, and facility costs. Even modest time savings can offset a higher product price when devices are used in high-volume procedures or multilayer closure.

A meta-analysis of V-Loc barbed sutures in gynecological surgery reported reductions in operation time, suturing time, blood loss, infection, and procedural difficulty without increasing postoperative complications or hospital stay. These findings support purchasing decisions based on total procedure economics rather than suture price alone.

Evidence is also extending beyond closure speed. Research covering abdominal procedures has associated barbed sutures with lower surgical-site infection rates and shorter hospital stays without a significant increase in fascial complications. Hospitals performing large procedure volumes can therefore evaluate knotless closure through infection-control, operating-room utilization, and episode-of-care costs rather than treating it only as a premium consumable.

Johnson & Johnson’s financial results provide a measurable commercial signal from the wider wound-closure industry. Its worldwide Surgery business generated USD 10.14 billion in 2025, increasing by 3.0% from USD 9.85 billion in 2024. General Surgery, which includes wound-closure products, generated USD 5.56 billion and accounted for approximately 54.8% of the company’s Surgery sales, while Advanced Surgery contributed USD 4.58 billion, or 45.2%. General Surgery revenue increased by 3.8%, and wound-closure products were identified as an important contributor to MedTech growth.

In the second quarter of 2026, Johnson & Johnson’s MedTech revenue reached USD 8.93 billion, rising 4.5% on a reported basis and 3.6% operationally. Wound closure and biosurgery were among the main contributors, strengthening the commercial case for differentiated surgical consumables within large hospital accounts.

 

Robotic Surgery Expands the Addressable Closure Environment

Knotless sutures are particularly relevant in laparoscopic and robotic surgery, where intracorporeal knot tying can add time and technical complexity. Self-anchoring designs can simplify selected suturing steps without replacing sutures with staples or adhesives.

Worldwide da Vinci procedure volume increased by 18% in 2025, while Intuitive Surgical expects another 13% to 15% increase during 2026. The continuing double-digit procedure growth expands the number of hysterectomy, myomectomy, prostatectomy, bariatric, hernia, and colorectal operations in which barbed closure may provide a workflow advantage.

The connection between procedural growth and recurring surgical revenue is visible in Intuitive Surgical’s results. First-quarter 2026 revenue reached USD 2.77 billion, increasing 23% from USD 2.25 billion in the first quarter of 2025. Instruments and accessories generated USD 1.69 billion, also increasing 23%, and represented approximately 61% of quarterly revenue. This recurring consumables mix demonstrates the financial importance of products consumed during minimally invasive procedures, even though robotic accessories and knotless sutures operate in separate product categories.

Robotic growth does not automatically convert into knotless-suture adoption. Product selection remains influenced by surgeon training, procedural preference, hospital contracts, and product-specific indications. However, the expansion of robotic surgery increases the number of cases in which knot tying is more difficult and closure efficiency carries greater economic value.

 

Cesarean Delivery Creates a High-Volume Surgical Opportunity

Cesarean delivery is one of the largest recurring procedure pools connected to knotless closure because uterine and abdominal layers require suturing. The United States recorded 3,628,934 births in 2024, and 32.4% were delivered by cesarean, representing approximately 1.18 million procedures. Cesarean delivery therefore accounted for nearly one-third of U.S. births and created a substantial annual closure opportunity.

Global opportunity is substantially larger. An estimated 29.7 million cesarean births were recorded across 169 countries in 2015. The World Health Organization subsequently reported that the worldwide cesarean share had increased from 6% in 1990 to approximately 21% and could approach 29% by 2030. Increasing procedure share, rather than population growth alone, expands the potential addressable base for uterine and abdominal-layer closure devices.

The commercial opportunity is concentrated in hospitals with high obstetric volumes, established surgical procurement, and physicians trained in barbed uterine closure. Adoption depends on evidence covering closure speed, uterine healing, scar quality, and outcomes in subsequent pregnancies. Suppliers that develop obstetric-specific evidence can strengthen access to maternal-health committees and standardized hospital protocols.

Cesarean procedures also demonstrate why prevalence-based demand estimates are less useful for this market. Revenue depends on product selection during a discrete surgical event, the number of layers closed, and the devices consumed during each case.

 

Joint Replacement Supports Repeatable Multilayer Closure

Total hip and knee arthroplasty represents another commercially attractive segment because these procedures often require long incisions and closure across several tissue layers. More than 1.2 million total hip and knee replacements are performed annually in the United States, while combined global annual demand exceeds 2 million procedures.

High case volumes, standardized surgical pathways, and pressure to improve operating-room throughput support the adoption of barbed sutures. Published studies have repeatedly associated knotless closure with shorter suturing time in joint replacement. In selected cases, operating-room savings can offset the higher material cost.

Orthopaedic conversion still depends heavily on surgeon preference. Hospitals may require product trials, value-analysis approval, and evidence that the suture performs consistently across the joint capsule, fascia, subcutaneous tissue, and skin. Manufacturers with multiple polymers, absorption profiles, and needle configurations can address more closure layers and secure a larger revenue contribution from each procedure.

The growth of outpatient joint replacement also strengthens the segment. Ambulatory surgery centers place greater emphasis on predictable case turnover, limited staffing, and standardized supply use, making closure efficiency commercially relevant when supported by measurable cost savings.

 

Hernia and Abdominal Surgery Provide the Largest Quantified Procedure Pool

More than 20 million groin-hernia repairs are performed worldwide each year, including over 800,000 in the United States. This makes hernia surgery the largest quantified annual procedure pool within the major applications discussed in the market. Global hernia volume is more than ten times the combined worldwide annual hip and knee replacement estimate and substantially exceeds current bariatric procedure volumes.

Barbed sutures may be used in selected abdominal-wall, peritoneal, mesh-fixation, and incision-closure steps. Evidence associating barbed sutures with lower surgical-site infection and shorter hospital stay gives this segment added commercial relevance. Hospitals performing large volumes of hernia, colorectal, gynecologic, and hepatobiliary procedures can evaluate knotless closure as part of infection-control and enhanced-recovery programs.

Product indication remains important because different barbed sutures are not automatically interchangeable across every tissue layer or surgical technique. Medtronic, for example, provides product-specific cautions for V-Loc devices and advises against leaving exposed barbed ends near the peritoneum. Clear indications and procedure-specific clinical evidence therefore influence hospital formulary decisions.

The hernia segment also offers potential for standardization. High-volume centers can adopt preferred closure protocols across open, laparoscopic, and robotic repairs, creating recurring demand for selected absorbable configurations.

 

Bariatric and Colorectal Surgery Add Focused High-Value Demand

The American Society for Metabolic and Bariatric Surgery estimated 270,089 U.S. metabolic and bariatric procedures in 2023. Sleeve gastrectomy accounted for 157,254 procedures, representing approximately 58.2% of the total. Roux-en-Y gastric bypass contributed 63,132 procedures, or 23.4%, while 32,267 revision procedures represented nearly 11.9%. These three subsegments together accounted for approximately 93.5% of U.S. bariatric procedure volume.

Sleeve gastrectomy therefore represents the most commercially relevant bariatric subsegment for closure suppliers, followed by gastric bypass and revision surgery. Their laparoscopic and robotic use creates demand for efficient running closure and tissue approximation.

Total bariatric volume declined from 279,967 procedures in 2022 to 270,089 in 2023, a reduction of approximately 3.5%, as obesity medicines changed patient treatment pathways. Despite the decline, fewer than 1% of eligible U.S. patients receive metabolic or bariatric surgery in a given year, preserving a large potential surgical population.

Colorectal surgery adds another high-value application. The United States is expected to record 158,850 new colorectal cancer cases in 2026, while more than 1.9 million new cases were recorded globally in 2022. Only a portion of patients undergo resection, but colectomy and low-anterior-resection procedures create opportunities for knotless closure in selected tissue layers.

These segments are commercially attractive because they combine complex minimally invasive procedures with pressure to reduce operative time and complications. Adoption depends more on surgeon conversion, case mix, and product indication than on disease prevalence alone.

 

Absorbable Devices Lead Product Demand

Absorbable knotless sutures form the commercial center of the market because they provide temporary tissue support and do not require later removal. Major portfolios include polydioxanone and shorter-duration absorbable copolymers designed for tissues with different healing periods.

Johnson & Johnson’s STRATAFIX Symmetric PDS Plus combines an absorbable polydioxanone strand with an antibacterial coating. Medtronic offers V-Loc 90 and V-Loc 180 configurations, while Corza, B. Braun, Healthium, Meril, WEGO/Foosin, and emerging manufacturers provide competing barbed designs.

Competition is shaped by absorption duration, directionality, anchoring design, tensile support, antibacterial protection, needle selection, and approved tissue use. Non-absorbable products retain demand where prolonged support is required, but their application base is narrower.

Hospitals are more likely to standardize several absorbable configurations because gynecology, general surgery, orthopaedics, bariatrics, urology, and colorectal surgery require different support periods. Suppliers with broad absorbable portfolios can increase revenue per account by serving multiple specialties and tissue layers.

 

Hospitals Dominate Purchasing, While Outpatient Surgery Raises Price Sensitivity

Hospitals remain the principal end users because major abdominal procedures, cesarean deliveries, arthroplasty, cancer resections, and complex robotic operations are concentrated in operating rooms with formal procurement systems.

Adoption usually requires surgeon support, infection-control review, value-analysis approval, and inclusion in procedure-specific supply lists. Large hospital systems can negotiate bundled wound-closure contracts, giving established suppliers an advantage through broader portfolios and distribution scale.

Ambulatory surgery centers represent a faster-growing but more price-sensitive opportunity. These facilities prioritize case turnover, limited staffing, predictable workflow, and standardized inventories. A higher-priced knotless suture must demonstrate measurable savings through reduced closure time, lower complication risk, or increased daily procedure capacity.

 

North America Leads, While Asia-Pacific Strengthens Competition

North America leads the commercial landscape through high surgical volumes, established medical-device purchasing, widespread robotic surgery, and the presence of Johnson & Johnson, Medtronic, Corza Medical, and emerging suppliers. The United States alone performs more than 1.2 million hip and knee replacements, approximately 1.18 million cesarean deliveries, over 800,000 inguinal-hernia repairs, and more than 270,000 bariatric procedures annually.

Johnson & Johnson’s geographic Surgery revenue illustrates the global distribution of commercial demand. The company generated USD 4.16 billion from U.S. Surgery sales in 2025, accounting for approximately 41% of its worldwide Surgery revenue. International sales reached USD 5.98 billion and represented 59%. U.S. Surgery revenue increased by 3.9%, compared with 2.4% reported growth internationally.

Asia-Pacific is the most strategic expansion region because it combines large surgical populations with increasing domestic manufacturing. WEGO/Foosin received FDA clearance for its PDO barbed suture in 2020, while India-based Meril received clearance for its PINION PDO and PGA-PCL knotless sutures. Healthium also sells barbed products through an international network.

These companies can increase pricing pressure and compete for tenders across emerging healthcare systems. Regional manufacturers may also benefit from lower production costs, local distribution, and government efforts to expand domestic medical-device capacity.

Europe maintains meaningful demand through established minimally invasive surgery, centralized hospital procurement, and suppliers such as B. Braun. Adoption is supported by evidence linking closure products with operating efficiency, infection reduction, and shorter hospital stays.

 

Regulatory Activity Broadens the Competitive Field

The FDA regulates knotless tissue control devices as surgical sutures, with absorbable polydioxanone products generally reviewed through the 510(k) pathway. The growing number of substantially equivalent devices is broadening supplier participation.

Sutura Medical Technology received FDA clearance for a barbed PDO suture in June 2026. Meril’s PINION absorbable knotless portfolio received clearance in September 2025, adding PDO and PGA-PCL options. These entries expand competition beyond the historically recognized STRATAFIX, V-Loc, and Quill brands.

New suppliers must build surgeon confidence, distribution, clinical support, and tender access after regulatory clearance. Established companies retain advantages through broader wound-closure contracts, physician training, international regulatory coverage, and the ability to bundle knotless products with conventional sutures, staplers, energy devices, and biosurgery products.

 

Competitive Outlook and Revenue Direction

Johnson & Johnson MedTech generated USD 33.79 billion in 2025, increasing 6.1% from USD 31.86 billion in 2024. Its USD 10.14 billion Surgery business represented approximately 30% of MedTech revenue, while General Surgery accounted for about 16.5% of total MedTech sales. Wound-closure products were identified as a driver of General Surgery and MedTech growth, although knotless-device revenue is not disclosed separately.

Medtronic benefits from the V-Loc brand and its wider position in laparoscopic and robotic surgery. Corza Medical competes through Quill, while B. Braun supports Symmcora through its global surgical-suture operations. Healthium, WEGO/Foosin, Meril, and Sutura are widening the supplier base and may compete more aggressively on price, regional distribution, and private-label manufacturing.

Market growth will come mainly from replacing conventional sutures in selected procedures rather than creating a new surgical category. Cesarean delivery, hernia repair, arthroplasty, bariatric surgery, gynecology, colorectal surgery, urology, and plastic surgery already generate millions of closure events each year.

Operating-room efficiency provides the strongest near-term purchasing argument. Infection reduction, shorter hospital stay, and consistent tissue approximation can create greater long-term value when supported by procedure-specific evidence. Continued robotic growth, outpatient migration, and regulatory clearances will expand product choice while increasing pricing pressure.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 2.28 Billion
Revenue Forecast in 2032	USD 4.40 Billion
Overall Growth Rate	CAGR of 8.5% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Absorbable Knotless Tissue Control Devices, Non-absorbable Knotless Tissue Control Devices
By Application	General and Abdominal Surgery, Obstetrics and Gynecology, Orthopedic Surgery, Bariatric Surgery, Hernia Repair, Colorectal Surgery, Urological Surgery, Cardiovascular Surgery, Plastic and Reconstructive Surgery
By End User	Hospitals, Ambulatory Surgery Centers, Specialty Surgical Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Argentina, Saudi Arabia, United Arab Emirates, South Africa
Market Drivers	Rising adoption of minimally invasive surgical procedures; growing demand for faster and more consistent wound closure; reduced knot-related complications and operating-room time; increasing surgical volumes across general, gynecological, orthopedic, bariatric, and cardiovascular care
Customization Option	Available upon request